A5007777254- Acute Lymphoblastic Leukemia research
- Neuroblastoma Research and Treatments
- Childhood Cancer Survivors' Quality of Life
- Lymphoma Diagnosis and Treatment
- Lung Cancer Research Studies
- Acute Myeloid Leukemia Research
- Cancer, Hypoxia, and Metabolism
- Glioma Diagnosis and Treatment
- Chronic Myeloid Leukemia Treatments
- Parvovirus B19 Infection Studies
- Cancer therapeutics and mechanisms
- Antifungal resistance and susceptibility
- Cancer Treatment and Pharmacology
- Histiocytic Disorders and Treatments
- DNA Repair Mechanisms
- Neutropenia and Cancer Infections
- Congenital Diaphragmatic Hernia Studies
- CNS Lymphoma Diagnosis and Treatment
- Palliative Care and End-of-Life Issues
- Cancer Risks and Factors
- Cancer survivorship and care
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Fungal Infections and Studies
- Ocular Infections and Treatments
Iaso Children’s Hospital
2014-2024
Children's Hospital Agia Sophia
2012-2024
National and Kapodistrian University of Athens
2005-2024
Comenius University Bratislava
2023
Universitätsmedizin Greifswald
2023
University Hospital Bratislava
2023
Senologic Hellenic Society
2021
University of Thessaly
2018
Boston Children's Hospital
2004-2014
Institute of Cancer Research
2014
To evaluate the hypothesis that detection of neuroblastoma mRNAs by reverse transcriptase quantitative polymerase chain reaction (RTqPCR) in peripheral blood (PB) and bone marrow aspirates (BM) from children with stage 4 are clinically useful biomarkers risk.
To evaluate the impact of surgeon-assessed extent primary tumor resection on local progression and survival in patients International Society Pediatric Oncology Europe Neuroblastoma Group High-Risk 1 trial.Patients recruited between 2002 2015 with stage 4 disease > year or 4/4S MYCN amplification < who had completed induction without progression, achieved response criteria for high-dose therapy (HDT), no before were included. Data collected excision, severe operative complications, outcome.A...
To reduce the incidence of febrile neutropenia during rapid COJEC (cisplatin, vincristine, carboplatin, etoposide, and cyclophosphamide given in a delivery schedule) induction. In High-Risk Neuroblastoma-1 (HR-NBL1) trial, International Society Paediatric Oncology European Neuroblastoma Group (SIOPEN) randomly assigned patients to primary prophylactic (PP) versus symptom-triggered granulocyte colony-stimulating factor (GCSF; filgrastim).From May 2002 November 2005, 239 16 countries were...
Abstract Background Risk stratification is crucial to treatment decision‐making in neuroblastoma. This study aimed explore factors present at diagnosis affecting outcome patients aged ≥18 months with metastatic neuroblastoma and develop a simple risk score for prognostication. Procedure Data were derived from the European high‐risk 1 (HR‐NBL1)/International Society Paediatric Oncology Neuroblastoma (SIOPEN) trial analysis restricted disease treated prior introduction of immunotherapy....
Induction therapy is a critical component of the high-risk neuroblastoma. We aimed to assess if Memorial Sloan Kettering Cancer Center (MSKCC) N5 induction regimen (MSKCC-N5) would improve metastatic complete response (mCR) rate and 3-year event-free survival (EFS) compared with rapid COJEC (rCOJEC; cisplatin [C], vincristine [O], carboplatin [J], etoposide [E], cyclophosphamide [C]).
Cisplatin is an essential chemotherapeutic agent for children treated with hepatic tumors, neuroblastoma, medulloblastoma, germ cell and osteosarcoma. Unfortunately, cisplatin-induced hearing loss (CIHL) occurs in about 50% of children,1-3 more frequent severe those aged less than or equal to 5 years.4, CIHL develops during the early stages therapy,4 irreversible,6 infants young causes speech language deficits, impaired academic skills, lower quality life.7, 8 Prevention has been variously...
Background Gonadal function in pediatric and young adult survivors of Hodgkin disease is not very well defined. This study evaluates the outcome following Multiple Drug Protocol (MDP) results are compared to published experience. Procedure Ovarian testicular was assessed 65 patients (36 males) with first or second complete remission after treatment either radiation (RT, n = 13), chemotherapy (CT, 9), both (n 43). Chemotherapy consisted six cycles MDP (doxorubicin, procarbazine, prednisone,...
In neuroblastoma (NB), the most powerful prognostic marker, MYCN amplification (MNA), occasionally shows intratumoural heterogeneity (ITH), i.e. coexistence of MYCN-amplified and non-MYCN-amplified tumour cell clones, called heterogeneous MNA (hetMNA). Prognostication therapy allocation are still unsolved issues.
2 The full, final text of this abstract will be available in Part II the 2011 Annual Meeting Proceedings, distributed onsite at on June 4, 2011, and as a supplement to 20, issue Journal Clinical Oncology.
One of the most frequent genes affected in pediatric ALL is CDKN2A/2B gene, acting as a secondary cooperating event and playing an important role cell-cycle regulation chemosensitivity. Despite its inclusion combined CNA (copy-number alterations) classifiers, like IKZF1plus entity UKALL profile, prognostic impact individual gene deletions outside context evaluation remains controversial. Addressing deletions’ additive effect current risk-stratification algorithms, we present retrospective...
Ototoxicity is an irreversible direct and late effect of certain childhood cancer treatments. Audiologic surveillance during therapy as part the supportive care pathway enables early detection hearing loss, decision-making about ongoing treatment, and, when applicable, timely use audiologic interventions. Pediatric oncologic clinical practice treatment trials have tended to be driven by tumor type tumor-specific working groups. Internationally accepted standardized recommendations for...
Neurotoxicity is an off-tumour, on-target side effect of GD2-directed immunotherapy with monoclonal antibodies. Here, we report the frequency, management and outcome patients enrolled in two prospective clinical trials who experienced severe neurotoxicity during anti-GD2 antibody dinutuximab beta (DB) administered as short-term infusion (HR-NBL1/SIOPEN study, randomisation R2, EudraCT 2006-001489-17) or long-term R4, 2006-001489-17 LTI/SIOPEN 2009-018077-31), either alone subcutaneous...
2 Background: The HR-NBL1 trial of the European SIOP Neuroblastoma Group randomised MAT regimens with primary aim to demonstrate superiority based on event free survival (EFS). Methods: At randomisation closure, 1,577 high-risk neuroblastoma patients (944 males) had been included since 2002; INSS stage 4 disease (1,369 pts) > 1 year, infants (65 and II III (143 any age MYCN amplification. Response eligibility criteria prior after Rapid COJEC Induction (J Clin Oncol, 2010) ± courses TVD...
Neuroblastoma comprises the most common neoplasm during infancy (first year of life). Our study describes incidence neuroblastoma in Southern-Eastern Europe (SEE), including - for first time Nationwide Registry Childhood Hematological Malignancies and Solid Tumors (NARECHEM-ST)/Greece, compared to US population, while controlling human development index (HDI). Age-adjusted rates (AIR) were calculated 1,859 childhood (0-14 years) cases, retrieved from 13 collaborating SEE registries...